Monitoring CAR-T cells activation and their cytotoxicity

CAR-T cells - a new immunotherapy strategy used in the destruction of tumor cells

CAR-T cells (for T cells carrying a chimeric receptor) are involved in gene therapies. The cells are made from the individual's own T-lymphocytes. When genetically modified and reinjected, they are capable of specifically recognizing and destroying cancer cells after binding to the tumor antigen by releasing a mixture of cytokines and pro-inflammatory chemokines.

This literature review, based on several scientific publications, focuses on the activation of CAR-T cells in vitro, monitored by using our homogeneous technologies such as AlphaLISA™ and HTRF™. These research methods are simple and robust, while consuming a minimum of samples and providing results faster than ELISA tests.

See below the different points monitored by our technologies in this literature review:

• Measurement of cell proliferation and cytokine release
• Cytotoxicity tests: DELFIA Eu TDA in CAR-T co-culture
• Cytotoxicity percentage measurement of CD19-expressing target cell lines
• Measurement of IFN concentrations-γ

For research use only. Not for use in diagnostic procedures.